Back to papers
0
Article ? AI-assigned paper type based on the abstract. Classification may not be perfect — flag errors using the feedback button. Sign in to save

CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes

Machines 2025 11 citations ? Citation count from OpenAlex, updated daily. May differ slightly from the publisher's own count.
Oliver Schnell, Jaime P. Almandoz, Lisa Anderson, Katharine Barnard‐Kelly, Tadej Battelino, Matthias Blüher, Luca Busetto, Doina Catrinou, Antonio Ceriello, Xavier Cos, Thomas Danne, Colin Dayan, Stefano Del Prato, Beatriz Fernández‐Fernández, Paola Fioretto, Thomas Först, James R. Gavin, Francesco Giorgino, Per‐Henrik Groop, Igor Alexander Harsch, Hiddo J.L. Heerspink, Lutz Heinemann, Mahmoud Ibrahim, Michel Jadoul, Sarah Jarvis, Linong Ji, Naresh Kanumilli, Mikhail Kosiborod, Ulf Landmesser, Sofia Macieira, Boris Mankovsky, Nikolaus Marx, Chantal Mathieu, Barbara McGowan, Tatjana Milenković, Othmar Moser, Dirk Müller‐Wieland, Νικόλαος Παπάνας, Dipesh Patel, Andreas Pfeiffer, Dario Rahelić, Helena W. Rodbard, Lars Rydén, Elke Schäeffner, C Wendy Spearman, Alin Stirban, Frank Tacke, Pınar Topsever, Luc Van Gaal, Eberhard Standl

Summary

This report from the 10th CVOT Summit covers cardiovascular and kidney outcome trial results for multiple drugs, and includes discussion of environmental plastic pollution as an emerging cardiovascular risk factor. The summit highlighted growing evidence linking microplastic and chemical exposure to cardiovascular disease risk alongside sessions on diabetes, obesity, and precision medicine.

Body Systems
Cardiovascular Hepatic Renal

The 10th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on December 5-6, 2024. This year, discussions about cardiovascular (CV) and kidney outcome trials centered on the recent findings from studies involving empagliflozin (EMPACT-MI), semaglutide (STEP-HFpEF-DM and FLOW), tirzepatide (SURMOUNT-OSA and SUMMIT), and finerenone (FINEARTS-HF). These studies represent significant advances in reducing the risk of major adverse cardiovascular events (MACE) and improving metabolic outcomes in heart failure with preserved ejection fraction (HFpEF), chronic kidney disease (CKD), and obstructive sleep apnea (OSA). The congress also comprised sessions on novel and established therapies for managing HFpEF, CKD, and obesity; guidelines for managing CKD and metabolic dysfunction-associated steatotic liver disease (MASLD); organ crosstalk and the development of cardio-kidney-metabolic (CKM) syndrome; precision medicine and person-centered management of diabetes, obesity, cardiovascular disease (CVD) and CKD; early detection of type 1 diabetes (T1D) and strategies to delay its onset; continuous glucose monitoring (CGM) and automated insulin delivery (AID); cardiovascular autonomic neuropathy (CAN) and the diabetic heart; and the role of primary care in the early detection, prevention and management of CKM diseases. The contribution of environmental plastic pollution to CVD risk, the increasing understanding of the efficacy and safety of incretin therapies in the treatment of CKM diseases, and the latest updates on nutrition strategies for CKM management under incretin-based therapies were also topics of interest for a vast audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians, who actively engaged in online discussions. The 11th CVOT Summit will be held virtually on November 20-21, 2025 ( http://www.cvot.org ).

Read via DOI Download PDF

Share this paper

Post Share Share Pin Email